Details of the Drug Combination

General Information of Drug Combination (ID: DC9X220)

• Drug Combination Name: Acamprosate + LY03004
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  Acamprosate (DMO381I): Small molecular drug
  LY03004 (DME5TUR): N.A.
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 26.9
  Bliss Independence Score: 26.9
  Loewe Additivity Score: 40.09
  LHighest Single Agent (HSA) Score: 40.09

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Acamprosate

Disease Entry	ICD 11	Status	REF
Alcohol dependence	6C40.2	Approved	[2]

Acamprosate Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Glutamate receptor AMPA (GRIA)	TTAN6JD	NOUNIPROTAC	Agonist	[4]

Indication(s) of LY03004

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Phase 3	[3]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7106).
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. Addict Biol. 2009 Jul;14(3):328-37.